Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25311996 | 0.93 | ALDH1A1 (0.36) | MEN1HPGDKMT2AALDH1A1PTGS2 | |
| SCHEMBL25311998 | 0.93 | ALDH1A1 (0.36) | MEN1HPGDKMT2AALDH1A1PTGS2 | |
| SCHEMBL29736486 | 0.85 | HTR2C (0.34) | ALDH1A1PTGS2MTNR1A | |
| SCHEMBL21955183 | 0.85 | USP2 (0.41) | MEN1HPGDKMT2ANPSR1ALDH1A1 | |
| SCHEMBL21955182 | 0.85 | USP2 (0.41) | MEN1HPGDKMT2ANPSR1ALDH1A1 | |
| SCHEMBL29736506 | 0.84 | PTGS2 (0.33) | ALDH1A1PTGS2 | |
| SCHEMBL22017697 | 0.84 | PTGS2 (0.33) | ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL29736398 | 0.83 | ALDH1A1 (0.34) | ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL28588530 | 0.83 | ALDH1A1 (0.34) | ALDH1A1PTGS2 | |
| SCHEMBL22017120 | 0.77 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1IDO1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | MEN1 3521/4885HPGD 3062/4885KMT2A 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.